AngElle Bioengineering ApS: Financial statements 2024
CVR: 43155881
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
AngElle Bioengineering ApS (CVR 43155881) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 44,631 and a net result of DKK 38,363 compared with DKK -1,168 the year before. The profit margin was 86%. Equity in the 2024 report amounted to DKK 140,917. The solvency ratio was 100%.
- Revenue
- DKK 44,631
- Gross Profit
- DKK 38,363
- Profit/Loss
- DKK 38,363
- Equity
- DKK 140,917
- Total Assets
- DKK 140,917
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 45 t. | 38 t. | 38 t. | 141 t. | - |
| 2023 | 0 | -1 t. | -1 t. | 103 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
AngElle Bioengineering ApS has published its annual report for 2023. Revenue came to DKK 0, and the net result was DKK -1,168.
About AngElle Bioengineering ApS
AngElle Bioengineering ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2022. The company is registered under the industry Anden teknisk rådgivning. The management consists of Irini Angelidaki. The company is owned by Irini Angelidaki. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -58,328 compared with DKK 38,363 the year before. Equity in the 2025 report amounted to DKK 82,579.